Article Versions Notes

Dellapasqua S, Trillo Aliaga P, Munzone E, Bagnardi V, Pagan E, Montagna E, Cancello G, Ghisini R, Sangalli C, Negri M, et al. Pegylated Liposomal Doxorubicin (Caelyx^®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. Current Oncology. 2021; 28(6):5167-5178. https://doi.org/10.3390/curroncol28060433

Dellapasqua, Silvia, Pamela Trillo Aliaga, Elisabetta Munzone, Vincenzo Bagnardi, Eleonora Pagan, Emilia Montagna, Giuseppe Cancello, Raffaella Ghisini, Claudia Sangalli, Mara Negri, and et al. 2021. "Pegylated Liposomal Doxorubicin (Caelyx^®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial" Current Oncology 28, no. 6: 5167-5178. https://doi.org/10.3390/curroncol28060433

Dellapasqua, S., Trillo Aliaga, P., Munzone, E., Bagnardi, V., Pagan, E., Montagna, E., Cancello, G., Ghisini, R., Sangalli, C., Negri, M., Mazza, M., Iorfida, M., Cardillo, A., Sciandivasci, A., Bianco, N., De Maio, A. P., Milano, M., Campennì, G. M., Sansonno, L., ... Colleoni, M. (2021). Pegylated Liposomal Doxorubicin (Caelyx^®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. Current Oncology, 28(6), 5167-5178. https://doi.org/10.3390/curroncol28060433